<DOC>
	<DOCNO>NCT02368301</DOCNO>
	<brief_summary>The objective expand access program provide treatment elotuzumab combination lenalidomide dexamethasone patient relapse refractory multiple myeloma U.S. site license physician determine clinical need .</brief_summary>
	<brief_title>Expanded Access Treatment Protocol CA204-143</brief_title>
	<detailed_description />
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Dexamethasone acetate</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Dexamethasone 21-phosphate</mesh_term>
	<mesh_term>Lenalidomide</mesh_term>
	<mesh_term>BB 1101</mesh_term>
	<criteria>For information regard BMS clinical trial participation , please visit www.BMSStudyConnect.com Men woman 18 year older Active , relapse refractory multiple myeloma IMWG ( International myeloma Working Group ) criterion assess treat physician receive one prior line multiple myeloma therapy Prior lenalidomide exposure permit fulfill follow : ) Were refractory prior lenalidomide define progression receive lenalidomide ( induction dose ) within 60 day last dose lenalidomide . Patients progress lenalidomide maintenance dose eligible enrolment . ii ) Patient discontinue lenalidomide due Grade ≥ 3 related AE Active plasma cell leukemia ( define either 20 % peripheral WBC comprise plasma/CD138+ cell absolute count 2 x 109/L ) . All Adverse Events prior chemotherapy , surgery , radiotherapy resolve NCI CTCAE ( v. 3.0 ) Grade ≤ 2 Significant cardiac disease determine treat physician include cardiac amyloidosis HIV infection active hepatitis A , B , C History participation elotuzumab study CA204004 , CA204006 CA204009 Inadequate recovery prior surgery prior myeloma therapy . If prior allogeneic stem cell transplant , history moderate severe chronic graft versus host disease ( GvHD ) Any medical condition , attend physician 's opinion , would impose excessive risk patient Certain abnormal physical laboratory finding Hypersensitivity lenalidomide , dexamethasone , excipients elotuzumab formulation , recombinant protein</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
</DOC>